Abstract
Bipolar disorder (BD) is known to be comorbid with many medical and psychiatric conditions and they may share inflammatory and stress-related aetiologies, which could give rise to this association. Psychosomatic illnesses are characterized by widespread immune signaling in the central nervous system, oxidative stress, and increased immune trafficking into the brain. The integrated stress response (ISR) responds to a variety of different stress conditions that lead to alterations in cellular homeostasis. However, as a causative mechanism underlying the cognitive deficits and neurodegeneration in a broad range of brain disorders, the impact of ISR on BD is understudied, particularly for the ISR’s central regulatory switch lies in eIF2 ternary complex formation. We aimed to prioritize eIF2-associated genes for follow-up studies using the summary data-based Mendelian Randomization (SMR) and Bayesian colocalization (COLOC) methods to integrate the summary-level data of the GWAS on BD and the expression quantitative trait locus (eQTL) study in blood. We utilized the GWAS data including 41917 BD cases and 371549 controls from the Psychiatric Genomics Consortium and the eQTL data from 31,684 participants of predominantly European ancestry from the eQTLGen consortium. Plus, we use Graph DB to alt drug targets. The SMR analysis identified EIF2B5 gene that were associated with BD due to no linkage but pleiotropy or causality. The COLOC analysis strongly suggested that EIF2B5 and the trait of BD were affected by shared causal variants, and thus were colocalized. Utilizing data in EpiGraphDB we find other putative causal BD genes (EIF2AK4 and GSK3B) to prioritise potential alternative drug targets.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The summary-level data of the GWAS on BD was publicly available from the Psychiatric Genomics Consortium (https://figshare.com/articles/dataset/bip2021_noUKBB/22564402/1). The eQTL dataset was publicly available from the eQTLGen consortium (https://www.eqtlgen.org/). V8 release of the GTEx eQTL/sQTL summary data can be downloaded from https://yanglab.westlake.edu.cn/software/smr/#DataResource.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The section on Introduction was updated to clarify why ISR and eiF2 are important to BD. Corrected some abbreviation errors in the text
